EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay Pharmaceuticals to report third quarter 2015 financial results and hold an investment community conference call on Friday, November 13, 2015.
Category: Business
Bruker Reports Third Quarter 2015 Financial Results
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Corporation (NASDAQ: BRKR) today reported financial results for its third quarter ended September 30, 2015. Bruker’s revenues for the third quarter of 2015 were $396.1 million, a decline of 5.6 percent compared to the third quarter of 2014. Excluding a 2.8 percent negative effect from divestitures, and a 10.9 percent negative effect from changes in foreign exchange rates, Bruker reported year-over-year organic revenue growth of 8.1 percent in the third
Acucela Validates Sampling Method That Could Pave Way for More Efficient Clinical Tests
SEATTLE–(BUSINESS WIRE)–Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel drug candidates to potentially treat and slow the progression of sight-threatening ophthalmic diseases, has validated an analytical method that could lead to significant cost savings in the collection of blood samples as part of the company’s clinical trials of emixustat hydrochloride (emixustat), the company announced today. Emixustat, the first inter
VISION EASE Expands Products and Market Availability with the Acquisition of Daemyung Optical Co. Ltd.
RAMSEY, Minn.–(BUSINESS WIRE)–Ophthalmic lens manufacturer VISION EASE immediately expands its product portfolio and distribution capabilities with the acquisition of Daemyung Optical Co. Ltd. (DMO).
ACADIA Pharmaceuticals to Present at the 24th Annual Credit Suisse Healthcare Conference on November 10, 2015
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that it will present at the 24th Annual Credit Suisse Healthcare Conference on Tuesday, November 10, 2015, at 11:30 a.m. Mountain Standard Time in Scottsdale, Arizona. A live webcast of ACADIA’s presentation will be accessible on the company’
Aerie Pharmaceuticals to Host Investor and Media Briefing During the 2015 American Academy of Ophthalmology Annual Meeting on November 13, 2015
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced that the Company will host a live webcast in conjunction with its Investor and Media Briefing during the 2015 American Academy of Ophthalmology Meeting on Frida…
Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics Reports Third Quarter 2015 Financial Results. Management to host conference call today at 8:30 a.m. ET
NovaBay Pharmaceuticals Completes 34 Patient Phase 2B Clinical Study
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, announces plans to report results from a clinical study with its proprietary anti-microbial compound auriclosene (NVC-422) to reduce urinary catheter blockage and encrustation in patients with long-term indwelling urinary catheters in early December. Due to spinal cord inj
Ocular Therapeutix™ to Report Third Quarter 2015 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report third quarter 2015 financial results on Tuesday, November 10, 2015. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 5:00 p.m. Eastern Time to r
Tobii AB Interim Report Q3 2015
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tobii AB (Nasdaq Stockholm: TOBII) today reported its results for the third quarter of 2015. Continued good progress in all business units July – September · The Group’s sales totaled SEK 228 million (168), an increase of SEK 60 million or 36%, of which SEK 30 million was currency effects and SEK 30 million was organic growth. · Gross margin was 72% (71%). · The Group’s operating loss amounted to SEK -8 million (-21). · The combined operating profit
Clinical Data Demonstrating Significant Improvements in Near and Intermediate Vision with ReVision Optics’ Raindrop Near Vision Inlay Published in Journal of Cataract Refractive Surgery
LAKE FOREST, Calif.–(BUSINESS WIRE)–ReVision Optics, Inc. (RVO), a leader in implantable presbyopia-correcting corneal inlay technology, announces that clinical data on the company’s Raindrop® Near Vision Inlay was published in the peer-reviewed Journal of Cataract Refractive Surgery. The Raindrop Inlay is a microscopic hydrogel inlay designed to improve near and intermediate vision, thus reducing the need for reading glasses. The article titled, “Range of refractive independence and mechanis
Ophthotech Corporation to Report Third Quarter 2015 Financial Results and Host Conference Call on Thursday, November 5, 2015
NEW YORK–(BUSINESS WIRE)–Ophthotech Corporation today announced that it will report its third quarter 2015 financial results on Thursday, November 5, 2015.
Research and Markets: Global Eyewear Market Report: 2015 Edition Featuring Essilor, Grand Vision, Luxottica & Safilo Group
DUBLIN–(BUSINESS WIRE)–Research and Markets (http://www.researchandmarkets.com/research/3tp4c7/global_eyewear) has announced the addition of the “Global Eyewear Market Report: 2015 Edition” report to their offering. The global eyewear market consists…
＜緊急告知その1＞ JINS MEMEが世界で一番早く手に入る！数量限定の先行発売イベント開催
東京–(BUSINESS WIRE)–（ビジネスワイヤ） — 株式会社ジェイアイエヌ（東京本社：東京都千代田区、代表取締役社長：田中仁）は、2015年11月5日（木）のJINS MEME一般発売に先駆け、11月3日（火・祝）13:00より東京・原宿のJINS MEMEフラッグシップストア原宿において50名様限定での(JINS MEME ES / JINS MEME MT）の先行発売イベントを行います。先行発売特典として度付レンズもしくはPCレンズへの無料交換対応を行うほか、オリジナル限定Tシャツをプレゼントいたします。 一般発売日の公開以降、かねてより発売を待ち望んでいた方々から多くの反響をいただいております。JINS MEMEの発売に期待を寄せる多くの皆様の気持ちに応えるために、JINS MEME専門店としてリニューアルするJINS MEMEフラッグシップストア原宿における数量限定先行発売を決定いたしました。 イベント概要 名 称 ： JINS MEME先行発売イベント 日 時 ： 2015年11月3日（火・祝）13:00より発売開始 場 所 ： JINS MEME フラッグ
Glaukos Corporation to Release Third Quarter 2015 Financial Results after Market Close on November 10
LAGUNA HILLS, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release third quarter 2015 financial results after the market close on Tuesday, November 10, 2015. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on Nov
Anthem Blue Cross and Blue Shield is Offering a $240 ‘New to Medicare’ Discount on Medicare Supplement Plan F in Colorado
DENVER–(BUSINESS WIRE)–Anthem Blue Cross and Blue Shield offers ‘New to Medicare’ Discount on Medicare Supplement Plan F in Colorado.
Improved Therapy for Cataract Patients Would Save Medicare Billions
NEW YORK–(BUSINESS WIRE)–A study reports that wider adoption of “dropless” therapy in connection with cataract surgeries could save Medicare and Medicaid more than $7.1 billion over the next ten years.
Ocular TherapeutixTM Reports on Topline Results of Phase 2b Glaucoma Clinical Trial
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results throug…
Ocular Therapeutix™ Announces Topline Results of Phase 3 Clinical Trial for DEXTENZA™ for the Treatment of Allergic Conjunctivitis
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, announced today topline efficacy results from a Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA™ (sustained release dexamethasone) 0.4 mg, Intracanalicular Depot for the treatment of allergic conjunctivitis. DEXTENZA is a product candidate administered by a phy
NovaBay Announces Proposed Public Offering of Common Stock and Warrants
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing and developing non-antibiotic antimicrobial products for the global eye care market, today announced that it intends to offer shares of its common stock and common stock purchase warrants in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be comple